• Catalpol in Osteoporosis and Disease Models: Applied Protoco

  2026-07-06

  Catalpol, a multi-pathway iridoid glycoside from APExBIO, transforms osteoporosis and neuroprotection research with reproducible performance and validated mechanisms. This article distills the latest reference study and practical workflows, empowering researchers to optimize Catalpol application in complex disease models.

• SAR131675: Precision VEGFR-3 Inhibitor for Lymphangiogenesis

  2026-07-06

  SAR131675 sets a new standard for dissecting lymphangiogenic and angiogenic signaling, offering exceptional selectivity and potency in both in vitro and in vivo models. This article translates recent research advances into actionable workflows and troubleshooting strategies, enabling researchers to interrogate VEGFR-3-driven pathways with confidence.

• Cimetidine as a Research Catalyst: BBB Modeling and Antitumo

  2026-07-05

  Explore how Cimetidine, a potent histamine-2 receptor antagonist, enables advanced blood-brain barrier modeling and antitumor research. This article offers a scientific deep dive into its unique pharmacological profile, practical protocols, and translational impact.

• Catalpol Mitigates Sepsis-Associated Cognitive Impairment vi

  2026-07-04

  This study demonstrates that Catalpol alleviates cognitive deficits in a mouse model of sepsis-associated encephalopathy by inhibiting NF-κB-mediated neuroinflammation and activating TrkB-dependent BDNF signaling. The findings provide robust mechanistic evidence for Catalpol’s dual-action neuroprotection and inform optimized use in translational research workflows.

• Octyl-α-ketoglutarate: Precision Tool for Prolyl Hydroxylase

  2026-07-03

  Octyl-α-ketoglutarate is unlocking new precision in hypoxia pathway research, offering uniquely stable and cell-permeable α-KG supplementation. Its robust performance in TCA cycle dysfunction and IDH mutation studies makes it a standout reagent for dissecting metabolic vulnerabilities in cancer.

• Thioredoxin System Modulates CHK1 Inhibitor Sensitivity in N

  2026-07-03

  This study uncovers the pivotal role of the thioredoxin (Trx) antioxidant system in determining the sensitivity of non-small cell lung cancer (NSCLC) cells to CHK1 inhibitors, by regulating ribonucleotide reductase (RNR) activity through redox mechanisms. The findings suggest new combinatorial strategies targeting redox pathways to enhance therapeutic efficacy and reduce toxicity in lung cancer treatment.

• Demethyleneberberine in NSCLC and Inflammation Models: Workf

  2026-07-02

  Demethyleneberberine (DMB) is redefining preclinical workflows as a multi-target anti-inflammatory and anti-cancer agent, with robust performance in cell and animal models. This article translates recent mechanistic advances into practical, stepwise protocols and troubleshooting strategies for maximizing DMB’s impact in oncology, inflammation, and neuroprotection research.

• Cyclopamine in Hedgehog Pathway Research: From Olfaction to

  2026-07-02

  Explore how Cyclopamine uniquely dissects Hedgehog signaling, not only in cancer research but also in sensory biology. This article reveals new assay insights and protocol guidance, with reference to breakthrough findings on Smo function.

• Genetic Mechanisms of Resistance to LDH Inhibitors in HTC Mo

  2026-07-01

  This study uses forward genetic screens to reveal two distinct resistance mechanisms—LDH isoform upregulation and compound-specific mutations—in Hürthle cell carcinoma (HTC) models treated with small molecule lactate dehydrogenase (LDH) inhibitors. These findings clarify the molecular adaptability of cancer metabolism, guiding future therapeutic strategies targeting metabolic vulnerabilities.

• Maximizing Proteasome Assay Precision with (R)-MG132 Control

  2026-07-01

  (R)-MG132 (SKU C3348) is a functionally inactive MG-132 enantiomer, serving as a rigorous negative control for proteasome inhibition studies. This article details scenario-driven laboratory challenges and demonstrates how (R)-MG132 ensures experimental specificity, reproducibility, and workflow clarity in cell-based assays.

• Partial BACE1 Inhibition Reduces Amyloid β Without Synaptic

  2026-06-30

  Satir et al. (2020) demonstrated that partial inhibition of BACE1 can lower amyloid β (Aβ) production by up to 50% without impairing synaptic transmission in primary neuronal cultures. These findings refine the therapeutic window for BACE inhibitors in Alzheimer's disease research, suggesting a moderate dosing strategy to preserve neuronal function.

• Deferoxamine Mesylate: Redefining Iron Chelation for Next-Ge

  2026-06-30

  Explore the multifaceted applications of Deferoxamine mesylate, a leading iron-chelating agent, in advanced oncological and hypoxia signaling research. This article uniquely bridges mechanistic insight with real-world assay design, informed by recent breakthroughs in ROS biology.

• Phosphoproteomic Remodeling in RCC Under Chronic Cabozantini

  2026-06-29

  This study applies quantitative phosphoproteomics to compare acute versus chronic Cabozantinib (XL184) exposure in renal cell carcinoma cells. The findings reveal timescale-dependent remodeling of phosphorylation networks and motility features, providing a detailed systems-level framework for understanding kinase inhibitor adaptation in RCC.

• Gene Regulation of Urethral Groove Formation in Guinea Pig v

  2026-06-29

  Wang and Zheng's 2025 study reveals that distinct temporal and spatial expression of Shh, Fgf10, and Fgfr2 genes underlies key differences in urethral groove and prepuce development between guinea pigs and mice. This work advances understanding of mammalian penile morphogenesis and provides mechanistic insight relevant to both developmental biology and teratogenicity research.

• Deferoxamine Mesylate: Iron-Chelating Agent for Advanced Res

  2026-06-28

  Deferoxamine mesylate stands out as a precision iron-chelating agent, enabling researchers to model iron homeostasis, study ferroptosis, and optimize hypoxia-mimetic assays with reproducible reliability. Its multifaceted applications in cancer biology, oxidative stress protection, and hypoxia signaling position it as a cornerstone reagent for translational workflows.

16581 records 1/1106 page Next 12345 下5页 Last page